1185855-70-2

Upstream product

• 1185281-04-2 C₁₈H₁₆N₄O 
• 409082-11-7 2-(2-methyl-5-nitrophenyl)acetonitrile 
• 449811-29-4 6-chloro-4-(methylamino)pyridine-3-carbaldehyde 
• 449811-28-3 ethyl 6-chloro-4-(methylamino)pyridine-3-carboxylate 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 409082-10-6 (2-methyl-5-nitrophenyl)-methyl methylsulfonate 
• 449811-30-7 (6-chloro-4-(methylamino)pyridin-3-yl)methanol 
• 1021535-31-8 3-(5-amino-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 850451-77-3 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 
• 22474-47-1 (2-methyl-5-nitro-7-phenyl)methanol 
• 1975-52-6 5-nitro-o-toluic acid 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 850449-93-3 methyl 2-(5-amino-2-methylphenyl)acetate 

Downstream Products

• 1185280-28-7 3-(5-(5-(3-hydroxycyclopentyl)-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185279-82-6 3-(5-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185279-55-3 1,7-dimethyl-3-(2-methyl-5-(5-phenyl-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 
• 1185280-32-3 (S)-1,7-dimethyl-3-(2-methyl-5-(5-(tetrahydrofuran-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 
• 1185280-06-1 3-(5-{[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]amino}-2-methylphenyl)-1,7-dimethyl-1,2-dihydro-1,6-naphthyridin-2-one 
• 1185280-03-8 1,7-dimethyl-3-(2-methyl-5-(5-(6-methylpyridin-3-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 
• 1185279-57-5 1,7-dimethyl-3-(2-methyl-5-(5-(thiazol-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 
• 1185280-23-2 3-(5-(5-isobutyl-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185279-85-9 3-(5-(5-(1-hydroxy-2-methylpropan-2-yl)-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-08-3 3-(5-(5-(2-hydroxy-2-methylpropyl)-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185281-09-7 methyl 1-(3-(3-(1,7-dimethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-methylphenylamino)-1,2,4-oxadiazol-5-yl)cyclopropanecarboxylate 
• 1185280-10-7 1,7-dimethyl-3-(2-methyl-5-(5-(1-(trifluoromethyl)cyclopropyl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 
• 1185280-31-2 (S)-3-(5-(5-(1-methoxyethyl)-1,2,4-oxadiazol-3-ylamino)-2-methylphenyl)-1,7-dimethyl-1,6-naphthyridin-2(1H)-one 
• 1185280-04-9 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds of Formula I: (I) pharmaceutical compositions comprising such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.